Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy

Clinical and Experimental Immunology

Volumn 173, Issue 1, 2013, Pages 131-139

  Zhou, Q ^a   Gil Krzewska, A ^a   Peruzzi, G ^b   Borrego, F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Monoclonal antibody; NK cell; Polyfunctionality; Tumour immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; CD3 ANTIGEN; CETUXIMAB; GAMMA INTERFERON; ILOMASTAT; IMMUNOGLOBULIN G1; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD SAMPLING; BREAST ADENOCARCINOMA; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL SURFACE; CONTROLLED STUDY; CROSS LINKING; CYTOKINE PRODUCTION; DEGRANULATION; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAJI CELL; SQUAMOUS CELL CARCINOMA; TARGET CELL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD3; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL DEGRANULATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; DIPEPTIDES; DOWN-REGULATION; GPI-LINKED PROTEINS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, IGG; SIGNAL TRANSDUCTION;

EID: 84878784248     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12095     Document Type: Article

References (42)

1. Jiang XR, Song A, Bergelson S etal. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-111.
2. Kohrt HE, Houot R, Marabelle A etal. Combination strategies to enhance antitumor ADCC. Immunotherapy 2012; 4:511-527.
3. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-287.
4. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012; 22:3-13.
5. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-640.
6. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-290.
7. Lanier LL, Yu G, Phillips JH. Analysis of Fc gamma RIII (CD16) membrane expression and association with CD3 zeta and Fc epsilon RI-gamma by site-directed mutation. J Immunol 1991; 146:1571-1576.
8. Vivier E, Morin P, O'Brien C, Druker B, Schlossman SF, Anderson P. Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J Immunol 1991; 146:206-210.
9. Mota G, Moldovan I, Calugaru A etal. Interaction of human immunoglobulin G with CD16 on natural killer cells: ligand clearance, FcgammaRIIIA turnover and effects of metalloproteinases on FcgammaRIIIA-mediated binding, signal transduction and killing. Scand J Immunol 2004; 59:278-284.
10. Grier JT, Forbes LR, Monaco-Shawver L etal. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 2012; 122:3769-3780.
11. Borrego F, Lopez-Beltran A, Pena J, Solana R. Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. Cell Immunol 1994; 158:208-217.
12. Grzywacz B, Kataria N, Verneris MR. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21:356-359; author reply 9.
13. Liu Q, Sun Y, Rihn S etal. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009; 83:8705-8712.
14. Verma RP, Hansch C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 2007; 15:2223-2268.
15. Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J Immunol 1991; 147:3459-3465.
16. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61:577-581.
17. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480-498.
18. Jackson C, Nguyen M, Arkell J, Sambrook P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis - targetting gelatinase A activation. Inflamm Res 2001; 50:183-186.
19. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart etal., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res 2003; 9:551-554.
20. Hatjiharissi E, Xu L, Santos DD etal. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007; 110:2561-2564.
21. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-446.
22. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294:15-22.
23. Pullyblank AM, Guillou PJ, Monson JR. Interleukin 1 and tumour necrosis factor alpha may be responsible for the lytic mechanism during anti-tumour antibody-dependent cell-mediated cytotoxicity. Br J Cancer 1995; 72:601-606.
24. Eller MA, Koehler RN, Kijak GH etal. Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in Ugandans carrying the HLA-B Bw4 motif. J Virol 2011; 85:4802-4811.
25. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502.
26. Lanier LL, Yu G, Phillips JH. Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells. Nature 1989; 342:803-805.
27. Lanier LL. Natural killer cell receptor signaling. Curr Opin Immunol 2003; 15:308-314.
28. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25:9-34.
29. Herszenyi L, Lakatos G, Hritz I, Varga MZ, Cierny G, Tulassay Z. The role of inflammation and proteinases in tumor progression. Dig Dis 2012; 30:249-254.
30. Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 2003; 63:8221-8225.
31. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13:781-792.
32. Dekkers PE, ten Hove T, Lauw FN etal. The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans. Infect Immun 2000; 68:3036-3039.
33. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13:95-109.
34. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11:397-408.
35. Wall L, Burke F, Barton C, Smyth J, Balkwill F. IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 2003; 9:2487-2496.
36. Soh J, Donnelly RJ, Kotenko S etal. Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell 1994; 76:793-802.
37. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000; 60:5673-5680.
38. Shankaran V, Ikeda H, Bruce AT etal. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-1111.
39. Betts MR, Nason MC, West SM etal. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789.
40. Boulet S, Song R, Kamya P etal. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol 2010; 184:2057-2064.
41. Ding ZC, Huang L, Blazar BR etal. Polyfunctional CD4(+) T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 2012; 120:2229-2239.
42. Wren L, Parsons MS, Isitman G etal. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS ONE 2012; 7:e38580.